Albumin Or Derivative Patents (Class 514/776)
  • Patent number: 9012518
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 21, 2015
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Patent number: 9012519
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 21, 2015
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Patent number: 8968783
    Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: March 3, 2015
    Assignee: Covidien LP
    Inventors: Steven Bennett, Nathaniel Mast, Kevin Lavigne, Walter Skalla
  • Patent number: 8871267
    Abstract: The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: October 28, 2014
    Assignee: Gel-Del Technologies, Inc.
    Inventor: David B. Masters
  • Patent number: 8853260
    Abstract: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: October 7, 2014
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong
  • Publication number: 20140296353
    Abstract: The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also provided.
    Type: Application
    Filed: February 26, 2014
    Publication date: October 2, 2014
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventors: Neil P. DESAI, Viktor PEYKOV, Patrick SOON-SHIONG
  • Patent number: 8846771
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: September 30, 2014
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Publication number: 20140242024
    Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: Covidien LP
    Inventors: Steven Bennett, Nathaniel Mast, Kevin Lavigne, Walter Skalla, Timothy Sargeant, Joshua Stopek
  • Publication number: 20140221289
    Abstract: The present invention relates to shear-thinning ?-lactalbumin hydrogels, which have a threshold and are thixotropic, to a method for preparing same and to the use thereof.
    Type: Application
    Filed: April 10, 2012
    Publication date: August 7, 2014
    Applicants: Commissariat a L'energie Atomique et Aux Energies Alternatives, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Vincent Forge, Carole Mathevon, Frédéric Pignon
  • Patent number: 8715737
    Abstract: The present invention relates a method to make porous materials which are useful in pharmaceutical, medicine, industry, and agriculture. The most advantage of the porous materials is to provide extremely large surface area for further modification and to incorporate a bioactive reagent in a mild condition to make the porous materials bioactive, biocompatible and biodegradable.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: May 6, 2014
    Inventor: Zhuo Joe Zhang
  • Publication number: 20140112961
    Abstract: A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure.
    Type: Application
    Filed: November 21, 2013
    Publication date: April 24, 2014
    Inventor: Cuthbert O. SIMPKINS
  • Publication number: 20140107227
    Abstract: The present invention relates to mucoadhesive drug delivery devices and their methods of preparation and use. More specifically the present invention relates to mucoadhesive drug delivery devices comprising one or more biocompatible purified proteins combined with one or more biocompatible solvents and one or more mucoadhesive agents. The mucoadhesive drug delivery devices may also include one or more pharmacologically active agents. The drug delivery devices of the present invention adhere to mucosal tissue, thereby providing a vehicle for delivery of the pharmacologically active agent(s) through such tissue.
    Type: Application
    Filed: September 10, 2013
    Publication date: April 17, 2014
    Inventors: David B. Masters, Eric P. Berg
  • Publication number: 20140039070
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Application
    Filed: February 26, 2013
    Publication date: February 6, 2014
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventor: Abraxis BioScience, LLC
  • Publication number: 20140039069
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Application
    Filed: February 26, 2013
    Publication date: February 6, 2014
    Applicant: ABRAXIS BIOSCIENCE, LLC
    Inventor: Abraxis BioScience, LLC
  • Patent number: 8642551
    Abstract: The invention comprises the use of LGF in the production of medicinal products that can be used in the pleiotropic tissue regeneration of one or more damaged tissues, in which at least one of the damaged tissues forms part of the central nervous system and the medicinal product is intended to be administered systemically. The invention is based on the fact that intraperitoneal administration of LGF can promote a positive effect on a Parkinson's disease model. As such, in a preferred embodiment of the invention, the medicinal product is intended for the treatment of Parkinson's disease, particularly when the medicinal product is intended for humans.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: February 4, 2014
    Inventor: Juan Jose Diaz Gil
  • Publication number: 20130315937
    Abstract: Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Applicant: The Ohio State University
    Inventors: Robert J. Lee, Young Bok Lee, Deog Joong Kim, Chang Ho Ahn
  • Publication number: 20130287820
    Abstract: Compositions for an oral delivery vehicle are described as well as methods for their manufacture and administration. The oral delivery vehicles can be made in any size or shape and can further comprise a medicament or other substance or object to be orally delivered. The vehicle can, for example, take the form of a pouch or capsule. Alternatively, a medicament or other substance to be orally delivered can be coated with the composition. In another alternative, the medicament or other substance to be orally delivered can be dispersed within a matrix of the composition. The compositions for the oral delivery vehicle are also suitable for use as an animal food or treat or use as a hunting bait or lure.
    Type: Application
    Filed: March 19, 2013
    Publication date: October 31, 2013
    Inventor: FOODSOURCE LURES CORPORATION
  • Publication number: 20130195983
    Abstract: The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 1, 2013
    Inventors: Neil P. Desai, Chunlin Tao, Tapas De, Sherry Xiaopei Ci, Vuong Trieu
  • Publication number: 20130195769
    Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Application
    Filed: March 11, 2013
    Publication date: August 1, 2013
    Applicant: FOAMIX LTD.
    Inventor: Foamix Ltd.
  • Publication number: 20130136775
    Abstract: A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.
    Type: Application
    Filed: November 30, 2011
    Publication date: May 30, 2013
    Inventors: Andreas Voigt, Jörg Kriwanek, Scott Hampton, Andreas Reiff, Sonja Ludwig
  • Patent number: 8445647
    Abstract: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: May 21, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Kathryn S. Prickett, Andrew A. Young
  • Publication number: 20130071412
    Abstract: The invention features a powdered composition including a pharmaceutically active compound and a protein or a hydrolyzed protein. In particular, the powdered composition forms a stable solution or dispersion suitable for oral administration in which the protein or the hydrolyzed protein is bound to the pharmaceutically active compound. The invention also provides a method of administering the composition, such as to a patient with dysphasia; liquid or semi-solid formulations of the composition; methods for preparing the composition; and kits including the composition.
    Type: Application
    Filed: December 17, 2010
    Publication date: March 21, 2013
    Applicant: Exodos Life Sciences Limited Partnership
    Inventors: Harry J. Leighton, Crist J. Frangakis
  • Patent number: 8367116
    Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: February 5, 2013
    Assignee: Seacoast Neuroscience, Inc.
    Inventors: Daniel Pratt, Samuel S. Macausland, Keith Baker
  • Publication number: 20130030282
    Abstract: The present invention discloses Near Infrared (NIR) fluorescent albumin nanoparticles having a structure selected from a core structure or a core-shell structure. Also disclosed are a process of preparing these NIR fluorescent albumin nanoparticles, and a method of in vivo detection of pathologies, in particular cancer pathology, by using administering these NIR fluorescent albumin nanoparticles to a patient.
    Type: Application
    Filed: July 17, 2012
    Publication date: January 31, 2013
    Applicant: BAR ILAN UNIVERSITY
    Inventors: Shlomo Margel, Sarit Cohen, Enav Corem Salkmon, Michal Pellach
  • Patent number: 8362091
    Abstract: A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: January 29, 2013
    Assignee: Foamix Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
  • Publication number: 20130011370
    Abstract: Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: The Children's Hospital of Philadelphia
    Inventors: Robert J. Levy, Boris Polyak, Michael Chorny, Ilia Fishbein, Ivan Alferiev, Gennady Friedman, Darryl Williams
  • Publication number: 20120308644
    Abstract: Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration to mucosal surface, such as oral, gastrointestinal and nasal mucosa. The compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.
    Type: Application
    Filed: August 6, 2012
    Publication date: December 6, 2012
    Inventors: Philip James Bromley, Lee Nickols Huang
  • Patent number: 8314156
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: November 20, 2012
    Assignee: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Patent number: 8309520
    Abstract: The present invention relates to a fully synthetic albumin analog, to a hemocompatible coating for medical devices containing the fully synthetic albumin analog, as well as to medical devices coated with the hemocompatible coating. The albumin analog preferably has two basic structures which are connected with one another via at least one bridging unit, the basic structures respectively having, in a geometrically defined manner, at least two bound joint regions to which at least one residue is covalently bound, wherein the basic structures are, respectively, a benzene carboxylic acid, and wherein the joint regions are formed via acid amide bonds, and wherein each residue, respectively, comprises a lipophilic region and a hydrophilic region.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: November 13, 2012
    Assignee: LS MedCap GmbH
    Inventor: Hans-Dieter Lehmann
  • Publication number: 20120283205
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Application
    Filed: February 7, 2012
    Publication date: November 8, 2012
    Inventors: Neil P. DESAI, Patrick Soon-Shiong, Vuong Trieu
  • Publication number: 20120207799
    Abstract: Natural, biodegradable compositions are described as well as methods for their manufacture. Fishing lures and other items made of the biodegradable materials disintegrate over time in fresh or salt water to reduce pollution. The materials are digestable by fish and other aquatic animals, reducing potential harm to the animal from ingesting a fishing lure or other item made from the natural biodegradable materials disclosed. Because the material is digestable, it can also be used as a food source or supplement for fish and aquatic animals.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 16, 2012
    Applicant: FOODSOURCE LURES CORPORATION
    Inventors: Ed ROGERS, Roy W. GILBERT
  • Patent number: 8138229
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: March 20, 2012
    Assignee: Abraxis Bioscience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Publication number: 20110319499
    Abstract: The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease, hi particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical biomarker in diagnostics to identify people who are at a higher risk of developing adverse ageing-related outcomes.
    Type: Application
    Filed: June 30, 2009
    Publication date: December 29, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Richard David Semba, Luigi Ferruci, Edward G. Lakatta
  • Publication number: 20110301248
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Application
    Filed: October 22, 2010
    Publication date: December 8, 2011
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Publication number: 20110300127
    Abstract: It is an object of the present invention to provide a drug-containing composition capable of stably retaining a water-soluble compound without the loss of drug efficacy of a pharmaceutically active ingredient and thus preventing the compound from diffusing in the body, which is unlikely to cause disassociation at a non-target site and thus achieves disassociation/sustained release/delivery specifically at a target site. The present invention provides a composition which is composed of: (a) at least one a water-soluble compound; and (b) a carrier comprising a polymer having binding affinity with the water-soluble compound.
    Type: Application
    Filed: May 27, 2009
    Publication date: December 8, 2011
    Applicant: FUJIFILM CORPORATION
    Inventors: Kentaro Nakamura, Shouji Ooya, Tetsuo Hiratou
  • Publication number: 20110268666
    Abstract: A novel gastroretentive delivery system comprising a tablet comprising a pharmaceutical ingredient or diagnostic, which tablet comprises a gas releasing ingredient or a tandem of two gas releasing ingredients, an ingredient capable of unrestricted swelling in gastric fluid, an ingredient capable of limiting the unrestricted swelling and a hardening ingredient. The said system is based on the use of three different gastroretentive mechanisms: flotation, swelling and mechanical strength, the three mechanisms acting in a complimentary way. Processes for manufacturing same and methods of treatment are also disclosed.
    Type: Application
    Filed: September 29, 2009
    Publication date: November 3, 2011
    Inventors: Michael Friedman, David Kirmayer
  • Publication number: 20110238000
    Abstract: A hydrogel system comprising polymer-conjugated albumin molecules is provided for controlled release delivery of therapeutic agents. The polymer is a functionalized synthetic polymer, preferably PEG-diacrylate. The polymer-conjugated albumin is preferably mono-PEGylated albumin. The hydrogel system may comprise a matrix to which the polymer-conjugated albumin molecules are linked via a functional group of the polymer. The matrix may be formed from the same polymer of the polymer-albumin conjugate.
    Type: Application
    Filed: December 7, 2009
    Publication date: September 29, 2011
    Applicant: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
    Inventors: Dror Seliktar, Liat Oss-Ronen
  • Publication number: 20110176997
    Abstract: The present invention relates a method to make porous materials which are useful in pharmaceutical, medicine, industry, and agriculture. The most advantage of the porous materials is to provide extremely large surface area for further modification and to incorporate a bioactive reagent in a mild condition to make the porous materials bioactive, biocompatible and biodegradable.
    Type: Application
    Filed: January 21, 2010
    Publication date: July 21, 2011
    Inventor: Zhuo Joe Zhang
  • Patent number: 7939099
    Abstract: A long-acting improver of muscular fatigue characterized by comprising 4 kinds of amino acids made up of leucine, isoleucine, valine and glutamine, and a whey protein component (whey protein and/or decomposition product of whey protein). At least one of a whey protein isolate (WPI), a whey protein concentrate (WPC), ?-lactoglobulin, and ?-lactalbumin is used as the whey protein. Novel food or drink, and pharmaceuticals which exhibit sustained recovery effects on muscular fatigue are provided.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: May 10, 2011
    Assignees: Meiji Dairies Corporation, Kyowa Hakko Bio Co. Ltd.
    Inventors: Hiroshi Tsuchita, Masato Saito, Toshikazu Kamiya, Miho Komatsu
  • Patent number: 7923032
    Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: April 12, 2011
    Assignee: Seacoast Neuroscience, Inc.
    Inventors: Daniel Pratt, Samuel S. MacAusland, Keith Baker
  • Publication number: 20110064794
    Abstract: A protein-phospholipid dispersion preparation in a drug delivery system is provided, in which the weight ratio of protein to phospholipid is 1:300-300:1 and the particle size is between 5 nm and 1000 nm. The preparation process of the said preparation contains the mixture of protein phase and phospholipid phase and the homogenization process. The said drug delivery system can be used in many different pharmaceutical agents.
    Type: Application
    Filed: January 16, 2009
    Publication date: March 17, 2011
    Applicants: Shenyang Pharmaceutical University, Hangzhou Yuhong Pharmaceutical Science & Technology Co., Ltd.
    Inventors: Yihui Deng, Xiaohui Dong, Li Shi, Yi Lu
  • Publication number: 20110038913
    Abstract: An erodible prosthesis comprising alternate rates of erosion is disclosed, wherein said alternate rates of erosion can be selectively initiated. Some embodiments according to the invention may comprise an agent for initiating an alternative rate of erosion, such as, for example, a sensitizer, dissolution inhibitor, photo-acid generator, biochemically active additive, thermally activated catalyst, light activated catalyst, electromagnetic radiation activated catalyst, hydration activated catalyst, pH activated catalyst, low melting agent, and/or enzyme activated catalyst. One or more of the foregoing agents may be dispersed within one or more layers.
    Type: Application
    Filed: July 2, 2010
    Publication date: February 17, 2011
    Inventors: Michael S. Williams, Joseph M. DeSimone
  • Publication number: 20110009497
    Abstract: It is an object of the present invention to provide a drug-containing composition which is capable of dissolving a poorly water-soluble drug, has low toxicity to the human body, and has high binding affinity with drugs. The present invention provides a composition which is composed of: (a) at least one poorly water-soluble compound; and (b) a carrier comprising a polymer (excluding plasma protein) having binding affinity with the poorly water-soluble compound.
    Type: Application
    Filed: March 18, 2009
    Publication date: January 13, 2011
    Applicant: FUJIFILM CORPORATION
    Inventors: Kentaro Nakamura, Shouji Ooya, Tetsuo Hiratou
  • Publication number: 20100322993
    Abstract: The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal.
    Type: Application
    Filed: July 27, 2010
    Publication date: December 23, 2010
    Inventors: Juergen Mollenhauer, Karin Benz, Barbara Platz, Helmut Wurst, Reinout Stoop
  • Patent number: 7837878
    Abstract: The present invention relates to a method and system for using a hemofilter to treat IMRD, hepatic failure, exogenous intoxication and other conditions associated with toxins in a patient's blood. One treatment includes the use of a very large pore hemofilter to remove target complex molecules and/or target molecules from a patient's blood and to infuse a replacement fluid into the patient's blood to maintain a prescribed albumin concentration in the patient's blood.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: November 23, 2010
    Assignee: Immunocept, L.L.C.
    Inventors: David Radunsky, James R. Matson, Patrice A. Lee
  • Publication number: 20100209353
    Abstract: The present invention relates to a protein conjugate having excellent tumor targeting capacity and a method for preparing the same, more precisely albumin-bile acid conjugate forming 30-500 nm nano-particles and forming self-aggregates in water system and a method for preparing the same. The albumin-bile acid conjugate of the present invention has excellent tumor targeting capacity and facilitates inclusion of a hydrophobic anticancer agent and can be combined with fore infrared ray fluorescent material. Therefore, this conjugate can be effectively used for the production of a novel nano-particle contrast agent or a nano-particle drug delivery system for the diagnosis and treatment of cancer.
    Type: Application
    Filed: March 23, 2009
    Publication date: August 19, 2010
    Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ick Chan KWON, Kwang Meyung KIM, Kuiwon CHOI
  • Publication number: 20100166874
    Abstract: Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals of defined dimensions.
    Type: Application
    Filed: December 8, 2009
    Publication date: July 1, 2010
    Inventors: Michael P. Malakhov, Fang Fang
  • Patent number: 7704518
    Abstract: A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: April 27, 2010
    Assignee: Foamix, Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
  • Patent number: 7700549
    Abstract: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: April 20, 2010
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Nigel Robert Arnold Beeley, Kathryn S. Prickett, Sunil Bhavsar, Andrew Young
  • Patent number: 7683030
    Abstract: Modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: March 23, 2010
    Assignee: Amylin Pharmaceuticals, Inc.
    Inventors: Kathryn S. Prickett, Andrew A. Young